American Society of Hirudotherapy

Pelvic Congestion Syndrome (Investigational Adjunct)

Investigational adjunct for pelvic congestion syndrome; medical therapy (progestins, GnRH analogs) and ovarian vein embolization remain evidence-based.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for pelvic congestion syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational with no controlled trials.
What evidence exists?
Tier C (investigational). Only anecdotal central European case reports exist. Pelvic congestion syndrome is chronic pelvic pain from ovarian and pelvic vein insufficiency with retrograde flow, most common in women who have had multiple pregnancies. Evidence-based management includes medical therapy with progestins or GnRH analogs to suppress estrogen-driven venous dilation, and (more definitively) ovarian vein embolization with reported pain-improvement rates of 75 to 95 percent. Hysterectomy with bilateral salpingo-oophorectomy is reserved for refractory cases in patients past childbearing.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the lower abdomen for 5 to 10 days
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Triggering of additional pelvic-vein engorgement or pain during the early-bleed phase
  • Delay of evidence-based ovarian vein embolization, progestin therapy, or GnRH analog therapy
  • Topical leech effects are unlikely to reach the deep pelvic venous plexus where the disease lives
Who should not consider this
  • Pregnant patients (all trimesters)
  • Breastfeeding patients (relative)
  • Patients with active deep vein thrombosis
  • Patients with endometriosis or pelvic mass not yet worked up
  • Patients on anticoagulants or with severe anemia
  • Patients who have not been offered or considered ovarian vein embolization
What to ask your clinician
  • Has pelvic congestion been confirmed by Doppler ultrasound, CT or MR venography, or catheter venography?
  • Have other causes of chronic pelvic pain (endometriosis, fibroids, adhesions) been excluded?
  • Have I been offered or considered ovarian vein embolization, which has strong evidence support?
  • Have I trialed progestins or GnRH analogs?
  • Where exactly will the leech be placed, and how far from the femoral vein?
  • What is the realistic expected benefit given the disease lives in deep pelvic veins?
When to seek urgent care
  • Sudden severe pelvic, abdominal, or low-back pain
  • Heavy vaginal bleeding or passage of clots
  • Fever above 38.0 C / 100.4 F, chills, or pelvic tenderness (rule out PID)
  • New leg swelling, redness, or tenderness (rule out DVT)
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, warmth, pus, or red streaks around any bite site

What this does NOT mean

  • It does not address the underlying ovarian vein insufficiency — embolization is the evidence-based definitive treatment.
  • It is not appropriate during pregnancy, which transiently distends pelvic veins and is contraindicated.
  • It does not replace medical therapy with progestins or GnRH analogs, which have RCT support.
  • Only anecdotal evidence exists.

Clinical Profile

Category
gynecologic
ICD-10
N94.89, I86.2
Safety tier
medium

Evidence Summary

Pelvic congestion syndrome (PCS) is chronic pelvic pain from ovarian and pelvic vein insufficiency with retrograde flow, most common in multiparous women of reproductive age. Workup includes pelvic ultrasound with Doppler, CT or MR venography, and (definitively) catheter venography. Evidence-based management includes medical therapy with progestins or GnRH analogs to suppress estrogen-driven venous dilation, and (more definitively) ovarian vein embolization with reported pain-improvement rates of 75 to 95 percent. Hysterectomy with bilateral salpingo-oophorectomy is reserved for refractory cases in patients past childbearing. No published controlled trials of hirudotherapy exist for PCS. Anecdotal central European reports describe lower abdominal placement; whether topical venous effects reach the deep pelvic venous plexus is unclear.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Pregnancy (all trimesters) — affects pelvic venous physiology and contraindicated
  • Breastfeeding (relative)
  • Active deep vein thrombosis
  • Endometriosis or other pelvic pathology not worked up
  • Pelvic mass on imaging

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Pelvic Congestion Syndrome (Investigational Adjunct) — Hirudotherapy Evidence | ASH